GWM
LGND icon

Gilpin Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Gilpin Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$599 Buy
3
+1
+50% +$198 ﹤0.01% 564
2025
Q4 		$379 Buy
+2
New +$384 ﹤0.01% 494

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Gilpin Wealth Management's LGND Position: Q1 2026 in Review

Gilpin Wealth Management increased its Ligand Pharmaceuticals (LGND) stake by 50% in Q1 2026, buying an estimated $198 and bringing the position to 3 shares worth $599. The position accounts for ﹤0.01% of the portfolio, ranked #564.

Gilpin Wealth Management first reported a position in LGND in Q4 2025 and has held it in 2 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Gilpin Wealth Management held 3 shares of Ligand Pharmaceuticals worth $599 as of Q1 2026.
  • Gilpin Wealth Management bought 1 Ligand Pharmaceuticals share in Q1 2026, an estimated $198.
  • Ligand Pharmaceuticals made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q1 2026, its #564 holding.
  • Gilpin Wealth Management first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Gilpin Wealth Management's 13F filing for Q1 2026, filed 21 Apr 2026.